Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
BRISBANE, Calif., May 31, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a company overview at two investor conferences in early June.
Details of the presentations follow:
Primary Capital, The Investor Conference
Date: Sunday, June 4, 2017
Location: The Resort at Pelican Hill, Newport Beach, Calif.
7th Annual LD Micro Invitational
Date: Tuesday, June 6, 2017, 1:30 p.m. PT
Track: 5
Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.
In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at [email protected].
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
